Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
Korea (Korea)
Profile Icon Profile Icon
로그인 / 등록 UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      Q-VD-OPh, General Caspase Inhibitor

      BD Pharmingen™ Q-VD-OPh, General Caspase Inhibitor

      (RUO)
      Q-VD-OPh, General Caspase Inhibitor
      Flow cytometric analysis of apoptosis in human T-Cell leukemia. Jurkat cells (ATCC, TIB-152) were preincubated with either 20 μM Q-VD-OPh (left) or no inhibitor for 30 minutes and then either left untreated (right) or treated with 20 μM camptothecin (center) for 5 hours. Following incubation, cells were collected and stained with PE Annexin V (Cat. No. 556421) and 7-AAD (Cat. No. 559925) to identify cells undergoing apoptosis. Flow cytometry was performed on a BD LSRFortessa™ flow cytometry system. The results indicate that in camptothecin treated cells, approximately 37% of the cells were induced to undergo apoptosis. In both the inhibitor treated and untreated cells, approximately 1% of cells underwent apoptosis. Thus, the use of the general caspase inhibitor Q-VD-OPh reduced the level of apoptosis to that observed in the untreated control.
      Q-VD-OPh, General Caspase Inhibitor
      Flow cytometric analysis of apoptosis in human T-Cell leukemia. Jurkat cells (ATCC, TIB-152) were preincubated with either 20 μM Q-VD-OPh (left) or no inhibitor for 30 minutes and then either left untreated (right) or treated with 20 μM camptothecin (center) for 5 hours. Following incubation, cells were collected and stained with PE Annexin V (Cat. No. 556421) and 7-AAD (Cat. No. 559925) to identify cells undergoing apoptosis. Flow cytometry was performed on a BD LSRFortessa™ flow cytometry system. The results indicate that in camptothecin treated cells, approximately 37% of the cells were induced to undergo apoptosis. In both the inhibitor treated and untreated cells, approximately 1% of cells underwent apoptosis. Thus, the use of the general caspase inhibitor Q-VD-OPh reduced the level of apoptosis to that observed in the untreated control.
      제품 세부 정보
      Down Arrow Up Arrow


      BD Pharmingen™
      Q-VD-Oph Genl Caspase Inhibitor Pure
      Flow cytometry (Routinely Tested)
      AB_2869523
      Lyophilized in dimethyl sulfoxide (DMSO).
      RUO


      준비 및 보관

      Avoid multiple freeze-thaws of product.

      Store the lyophilized Q-VD-OPh inhibitor at –20°C. Reconstitute the Q-VD-OPh inhibitor in DMSO before use. The reconstituted Q-VD-OPh inhibitor may be stored in small aliquots at –20°C.

      자세히 보기 blue down arrow 간략히 보기 blue up arrow

      권장 분석 절차

      The Q-VD-OPh inhibitor is designed to be used in both in vivo and in vitro cell based assays to measure the inhibition of apoptosis.

      Reconstitute 1.0 mg of the Q-VD-OPh inhibitor in DMSO. A 10 mM stock solution may be made by dissolving 1.0 mg of Q-VD-OPh in 195 µl DMSO. The final concentration of inhibitor may vary between experimental systems and investigators are encouraged to titrate the inhibitor for optimal performance. As a precautionary note, do not exceed a final DMSO concentration of 0.2% as higher levels may cause cellular toxicity and mask the effects of the caspase inhibitor.

      자세히 보기 blue down arrow 간략히 보기 blue up arrow

      제품 고시

      1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
      2. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      자세히 보기 blue down arrow 간략히 보기 blue up arrow
      563828 Rev. 2
      항체 세부 정보
      Down Arrow Up Arrow

      The caspase family of cysteine proteases plays a key role in apoptosis and inflammation. Q-VD-OPh is a potent, cell-permeable inhibitor of caspase activity. It irreversibly inhibits the activity of a broad range of caspases, including caspases-1, -2, -3, -5, -6, -7, -8, -9, -10, and -12. Deemed a next generation caspase inhibitor, Q-VD-OPh has increased selectivity for the caspases over other cysteine proteases, increased potency, and decreased toxicity compared to the previous generation of caspase inhibitors. Additionally, other pan caspase inhibitors do not inhibit all caspases equally. Q-VD-OPh, in contrast, inhibits the spectrum of caspases more equally and at lower concentrations, thus making it a true broad spectrum caspase inhibitor.

      563828 Rev. 2
      인용 및 참고 문헌
      Down Arrow Up Arrow

      개발 참고 자료 (6)

      1. Brown TL. Q-VD-OPh, next generation caspase inhibitor. Adv Exp Med Biol. 2004; 559:293-300. (Biology). 참조 보기
      2. Caserta TM, Smith AN, Gultice AD, Reedy MA, Brown T. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis. 2003; 8(4):345-352. (Biology). 참조 보기
      3. Chauvier D, Ankri S, Charriaut-Marlangue C, Casimir R, Jacotot E. Broad-spectrum caspase inhibitors: from myth to reality. Cell Death Differ. 2007; 14(2):387-391. (Biology). 참조 보기
      4. Kuželová K, Grebeňová D, Brodská B. Dose-dependent effects of the caspase inhibitor Q-VD-OPh on different apoptosis-related processes. J Cell Biochem. 2011; 112(11):3334-3342. (Biology). 참조 보기
      5. Melnikov VY, Faubel S, Siegmund B, Lucia MS, Ljubanovic D, and Edelstein CL. Neutrophil-independent mechanisms of caspase-1– and IL-18–mediated ischemic acute tubular necrosis in mice. J Clin Invest. 2002; 110(8):1083-1091. (Biology). 참조 보기
      6. Thornberry NA, Rano TA, Peterson EP, et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem. 1997; 272(29):17907-17911. (Biology). 참조 보기
      모두 보기 (6) 간단히 보기
      563828 Rev. 2

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.

      Website Feedback